Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection

The fully human monoclonal antibody bezlotoxumab is indicated for preventing the recurrence of Clostridioides difficile (formerly Clostridium difficile) infection (CDI) in adults who receive antibacterial treatment for CDI and who are at high risk for a CDI recurrence. The efficacy and safety of 10-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Yee, Ka Lai, Kleijn, Huub Jan, Kerbusch, Thomas, Matthews, Randolph P., Dorr, Mary Beth, Garey, Kevin W., Wrishko, Rebecca E.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2019
Matèries:
Clinical Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355577/
https://ncbi.nlm.nih.gov/pubmed/30455246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01971-18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars